{
    "info": {
        "nct_id": "NCT06111235",
        "official_title": "A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)",
        "inclusion_criteria": "* Pathologically confirmed IR-NMIBC, per American Urologic Association/Society of Urologic Oncology/National Comprehensive Cancer Network guidelines, within 90 days of participant randomization:\n\n  1. Recurrent LG Ta within 12 months of prior LG or HG (HG Ta ≤ 3 cm) tumor\n  2. Solitary LG Ta >3 cm tumor\n  3. Multifocal LG Ta tumors\n  4. Primary and solitary HG Ta ≤3 cm tumor\n  5. LG T1 tumor\n* All visible disease removed by TURBT within 12 weeks of study randomization\n* Acceptable baseline organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* High-risk NMIBC (e.g., HG T1, Recurrent or multifocal HG Ta>3cm tumor(s), CIS)\n* Low-Risk NMIBC (e.g., solitary LG Ta ≤3 cm tumor)\n* Disease in the prostatic urethra at any time or in the upper genitourinary tract within 24 months of randomization\n* Muscle-invasive bladder cancer, locally advanced or metastatic bladder cancer\n* Prior treatment with any human adenovirus serotype 5 based therapy (e.g., Ad-interferon or Adstiladrin)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Acceptable baseline organ function",
            "criterions": [
                {
                    "exact_snippets": "Acceptable baseline organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "acceptable at baseline"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. LG T1 tumor",
            "criterions": [
                {
                    "exact_snippets": "LG T1 tumor",
                    "criterion": "tumor grade and stage",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "low grade"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "T1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All visible disease removed by TURBT within 12 weeks of study randomization",
            "criterions": [
                {
                    "exact_snippets": "All visible disease removed by TURBT",
                    "criterion": "visible disease",
                    "requirements": [
                        {
                            "requirement_type": "removal by TURBT",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 12 weeks of study randomization",
                    "criterion": "removal timing",
                    "requirements": [
                        {
                            "requirement_type": "time from study randomization to removal",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Multifocal LG Ta tumors",
            "criterions": [
                {
                    "exact_snippets": "Multifocal LG Ta tumors",
                    "criterion": "LG Ta tumors",
                    "requirements": [
                        {
                            "requirement_type": "focality",
                            "expected_value": "multifocal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Primary and solitary HG Ta ≤3 cm tumor",
            "criterions": [
                {
                    "exact_snippets": "Primary and solitary HG Ta ≤3 cm tumor",
                    "criterion": "tumor",
                    "requirements": [
                        {
                            "requirement_type": "primary",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "solitary",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "histological grade",
                            "expected_value": "high grade (HG)"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "Ta"
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Solitary LG Ta >3 cm tumor",
            "criterions": [
                {
                    "exact_snippets": "Solitary LG Ta >3 cm tumor",
                    "criterion": "tumor",
                    "requirements": [
                        {
                            "requirement_type": "number",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "tumor"
                            }
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": "low grade"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "Ta"
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathologically confirmed IR-NMIBC, per American Urologic Association/Society of Urologic Oncology/National Comprehensive Cancer Network guidelines, within 90 days of participant randomization:",
            "criterions": [
                {
                    "exact_snippets": "Pathologically confirmed IR-NMIBC",
                    "criterion": "IR-NMIBC (intermediate-risk non-muscle invasive bladder cancer)",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathological"
                        }
                    ]
                },
                {
                    "exact_snippets": "per American Urologic Association/Society of Urologic Oncology/National Comprehensive Cancer Network guidelines",
                    "criterion": "IR-NMIBC diagnosis guidelines",
                    "requirements": [
                        {
                            "requirement_type": "guideline adherence",
                            "expected_value": [
                                "American Urologic Association",
                                "Society of Urologic Oncology",
                                "National Comprehensive Cancer Network"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "within 90 days of participant randomization",
                    "criterion": "time since IR-NMIBC diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Recurrent LG Ta within 12 months of prior LG or HG (HG Ta ≤ 3 cm) tumor",
            "criterions": [
                {
                    "exact_snippets": "Recurrent LG Ta within 12 months of prior LG or HG",
                    "criterion": "recurrent LG Ta tumor",
                    "requirements": [
                        {
                            "requirement_type": "recurrence_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "prior_tumor_grade",
                            "expected_value": [
                                "LG",
                                "HG"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "HG Ta ≤ 3 cm",
                    "criterion": "HG Ta tumor size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Muscle-invasive bladder cancer, locally advanced or metastatic bladder cancer",
            "criterions": [
                {
                    "exact_snippets": "Muscle-invasive bladder cancer",
                    "criterion": "muscle-invasive bladder cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic bladder cancer",
                    "criterion": "bladder cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* High-risk NMIBC (e.g., HG T1, Recurrent or multifocal HG Ta>3cm tumor(s), CIS)",
            "criterions": [
                {
                    "exact_snippets": "High-risk NMIBC",
                    "criterion": "non-muscle invasive bladder cancer (NMIBC)",
                    "requirements": [
                        {
                            "requirement_type": "risk category",
                            "expected_value": "high-risk"
                        }
                    ]
                },
                {
                    "exact_snippets": "HG T1",
                    "criterion": "tumor stage and grade",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "T1"
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": "high grade"
                        }
                    ]
                },
                {
                    "exact_snippets": "Recurrent or multifocal HG Ta>3cm tumor(s)",
                    "criterion": "Ta tumor(s)",
                    "requirements": [
                        {
                            "requirement_type": "recurrence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "multifocality",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": "high grade"
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "CIS",
                    "criterion": "carcinoma in situ (CIS)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Low-Risk NMIBC (e.g., solitary LG Ta ≤3 cm tumor)",
            "criterions": [
                {
                    "exact_snippets": "Low-Risk NMIBC",
                    "criterion": "NMIBC risk category",
                    "requirements": [
                        {
                            "requirement_type": "risk category",
                            "expected_value": "Low-Risk"
                        }
                    ]
                },
                {
                    "exact_snippets": "solitary LG Ta ≤3 cm tumor",
                    "criterion": "tumor characteristics",
                    "requirements": [
                        {
                            "requirement_type": "number of tumors",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "tumor"
                            }
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": "low grade"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "Ta"
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with any human adenovirus serotype 5 based therapy (e.g., Ad-interferon or Adstiladrin)",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with any human adenovirus serotype 5 based therapy (e.g., Ad-interferon or Adstiladrin)",
                    "criterion": "prior treatment with human adenovirus serotype 5 based therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Disease in the prostatic urethra at any time or in the upper genitourinary tract within 24 months of randomization",
            "criterions": [
                {
                    "exact_snippets": "Disease in the prostatic urethra at any time",
                    "criterion": "disease in the prostatic urethra",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "at any time"
                        }
                    ]
                },
                {
                    "exact_snippets": "disease ... in the upper genitourinary tract within 24 months of randomization",
                    "criterion": "disease in the upper genitourinary tract",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "reference_event",
                            "expected_value": "randomization"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}